1
|
Sharma D, Pawar SN, Sulkshane P, Waghole R, Yasser M, Pawar SS, Kannan S, Chaudhary N, Kalwar A, Patil R, Nair S, Dalal SN, Teni T. Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome. J Oral Pathol Med 2023; 52:849-859. [PMID: 37573872 DOI: 10.1111/jop.13467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 06/28/2023] [Accepted: 07/05/2023] [Indexed: 08/15/2023]
Abstract
BACKGROUND Translationally controlled tumour protein (TCTP) is a multifunctional protein elevated in multiple cancers. However, studies on its role in oral carcinogenesis and prognosis are rare. We recently reported the role of its interacting partner, MCL1, in oral cancer progression and outcome. Hence, the present study aimed to assess TCTP expression in oral tumorigenesis and its association with patient outcomes alone and in combination with MCL1. METHODS TCTP expression was assessed by immunohistochemistry and immunoblotting in oral tissues and cells, respectively. Cell viability post siRNA/dihydroartemisinin treatment was analysed by tetrazolium salt assay. Cell survival, invasion and tumorigenic potential post TCTP knockdown were assessed by clonogenic, Matrigel and soft-agar assays, respectively. The association of TCTP with patient outcome was analysed by Kaplan-Meier and Cox regression. RESULTS TCTP was significantly overexpressed in oral premalignant lesions (p < 0.0001), oral tumours (p < 0.0001) and oral dysplastic and cancer cells versus normal oral mucosa and also in recurrent (p < 0.05) versus non-recurrent oral tumours. Further, elevated TCTP was significantly (p < 0.05) associated with poor recurrence free survival (RFS) and poor overall survival (OS; hazard ratio = 2.29; p < 0.05). Intriguingly, the high co-expression of TCTP and MCL1 further reduced the RFS (p < 0.05) and OS (p < 0.05; hazard-ratio = 3.49; p < 0.05). Additionally, TCTP knockdown decreased survival (p < 0.05), invasion (p < 0.01) and in vitro tumorigenic potential (p < 0.0001). Dihydroartemisinin treatment reduced TCTP levels and viability of oral cancer cells. CONCLUSION Our studies demonstrate an oncogenic role of TCTP in oral cancer progression and poor outcome. Thus, TCTP may be a potential prognostic marker and therapeutic target in oral cancers.
Collapse
Affiliation(s)
- Dipti Sharma
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
- Homi Bhabha National Institute (HBNI), Mumbai, India
| | - Sagar N Pawar
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Prasad Sulkshane
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Rohit Waghole
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Mohd Yasser
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Sushil S Pawar
- Department of Oral Pathology & Microbiology, KBH Dental College and Hospital, Nashik, India
| | - Sadhana Kannan
- Clinical Research Secretariat, ACTREC, TMC, Navi Mumbai, India
| | - Nazia Chaudhary
- Homi Bhabha National Institute (HBNI), Mumbai, India
- Cell and Tumor Biology, ACTREC, TMC, Navi Mumbai, India
| | - Anjali Kalwar
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Rahul Patil
- Department of Oral Pathology & Microbiology, KBH Dental College and Hospital, Nashik, India
| | - Sudhir Nair
- Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
| | - Sorab N Dalal
- Homi Bhabha National Institute (HBNI), Mumbai, India
- Cell and Tumor Biology, ACTREC, TMC, Navi Mumbai, India
| | - Tanuja Teni
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
- Homi Bhabha National Institute (HBNI), Mumbai, India
| |
Collapse
|
3
|
Yadav P, Kumar N, Kumar A, Kapoor A, Beniwal S, Kalwar A. Plasminogen activator inhibitor-1 promotes immunosuppression in cancer by modulating immune component of tumor microenvironment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy319.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Kumar N, Kapoor A, Kalwar A, Kumar A, Narayan S, Lal S, Beniwal S. 452P A phase II study of geftinib versus best supportive care as second or third line therapy in advanced squamous cell carcinoma of lung in Asian Indians. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Kapoor A, Kumar N, Kalwar A, Narayan S, Singhal M, Kumar A, Lal S. 423PD A prospective phase III study of three weekly versus weekly paclitaxel as second line therapy in advanced non small cell lung cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Kapoor A, Kumar N, Kalwar A, Narayan S, Nirban R, Jakhar S, Beniwal S, Sharma N, Kumar H, Sharma A. Allele Frequency of Abo and Rh Blood Group and the Risk of Non Small Cell Lung Carcinoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv043.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Kumar N, Kapoor A, Kalwar A, Narayan S, Singhal M, Kumar A, Lal S, Nirban R, Paramanandhan M, Purohit R. A Prospective Randomized Phase Iii Study of Palliative Chemotherapy Versus Best Supportive Care in Elderly Patients with Advanced Non-Small Cell Lung Cancer: Survival Analysis and Ecog Performance Status Regression Analysis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Sharma B, Kalwar A, Sharma N, Yadav V, Midha V, S.L SJ, Bisnoi SK. Is there need of Bone Scan Before Doing Breast Cancer Surgery? A Regional Cancer Centre Experience. Indian J Med Paediatr Oncol 2006. [DOI: 10.1055/s-0041-1733194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- B Sharma
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - A Kalwar
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - N Sharma
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - V Yadav
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - V Midha
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - S.L Jakhar S.L
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| | - S K Bisnoi
- Acharya Tulsi Regional Cancer Institute & S.P.Medical College & Hospital, Bikaner-Rajsthan, India
| |
Collapse
|